ALK and neoplasm: In conclusion, in this preliminary and exploratory study, we established a plasma microRNA panel that may serve as a novel, non-invasive biomarker for the diagnosis of ALK-positive NSCLC, and may provide considerable value as a predictor of tumor response to treatment with crizotinib.